M H Baumann

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity
    M H Baumann
    Medications Development Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 914:172-86. 2000
  2. ncbi N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Neuropsychopharmacology 30:550-60. 2005
  3. ncbi Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain
    Michael H Baumann
    Clinical Psychopharmacology Section, IRP, NIDA, National Institutes of Health, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 1025:189-97. 2004
  4. ncbi 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program IRP, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 189:407-24. 2007
  5. ncbi Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 965:92-108. 2002
  6. ncbi Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 301:1190-7. 2002
  7. ncbi In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Pharmacol Exp Ther 297:531-9. 2001
  8. ncbi Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 914:354-68. 2000
  9. ncbi Comparative neurobiological effects of ibogaine and MK-801 in rats
    M H Baumann
    Medications Discovery Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, PO Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 59:143-51. 2000
  10. ncbi Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Neurosci 18:9069-77. 1998

Detail Information

Publications64

  1. ncbi Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity
    M H Baumann
    Medications Development Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 914:172-86. 2000
    ..The relevance of this hypothesis for explaining clinical side effects of FEN and dFEN, such as cardiac valvulopathy and primary pulmonary hypertension, warrants further study...
  2. ncbi N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Neuropsychopharmacology 30:550-60. 2005
    ..Our results show that BZP/TFMPP and MDMA share the ability to evoke monoamine release, but dangerous drug-drug synergism may occur when piperazines are coadministered at high doses...
  3. ncbi Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain
    Michael H Baumann
    Clinical Psychopharmacology Section, IRP, NIDA, National Institutes of Health, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 1025:189-97. 2004
    ..Additionally, the findings suggest possible drug-drug synergism when piperazine drugs are coadministered at high doses...
  4. ncbi 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program IRP, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 189:407-24. 2007
    ..g., depletion of forebrain 5-HT) that have been interpreted as neurotoxicity. Whether such 5-HT deficits reflect neuronal damage is a matter of ongoing debate...
  5. ncbi Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 965:92-108. 2002
    ..The findings suggest that GBR-decanoate, or similar long-acting agents, should be evaluated further as potential treatment adjuncts in the management of METH addiction in humans...
  6. ncbi Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 301:1190-7. 2002
    ..Our data suggest that GBR-decanoate, or similar agents, may be useful adjuncts in treating methamphetamine dependence. This therapeutic strategy would be especially useful for noncompliant patient populations...
  7. ncbi In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Pharmacol Exp Ther 297:531-9. 2001
    ..More importantly, noribogaine appears less apt to produce the adverse effects associated with ibogaine, indicating the metabolite may be a safer alternative for medication development...
  8. ncbi Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 914:354-68. 2000
    ..Most importantly, NORIBO appears less likely to produce the adverse effects associated with IBO (i.e., tremors and stress-axis activation), suggesting that the metabolite may be a safer alternative for medication development...
  9. ncbi Comparative neurobiological effects of ibogaine and MK-801 in rats
    M H Baumann
    Medications Discovery Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, PO Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 59:143-51. 2000
    ..Thus, the wide spectrum of in vivo actions of ibogaine can probably not be explained simply on the basis of antagonism at NMDA receptors...
  10. ncbi Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Neurosci 18:9069-77. 1998
    ..FEN should remain an important pharmacological tool for determining the role of 5-HT neurons in mediating diverse physiological and behavioral processes...
  11. ncbi 1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Neuropsychopharmacology 24:492-501. 2001
    ..Our data support the notion that 5-HT release per se may not be sufficient to produce the long-term 5-HT deficits associated with d-fenfluramine and other amphetamines...
  12. ncbi Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse
    R B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, Baltimore, Maryland, USA
    Synapse 35:222-7. 2000
    ..The major finding reported here is that indatraline blocks the ability of METH and MDMA to release these neurotransmitters. Synapse 35:222-227, 2000. Published 2000 Wiley-Liss, Inc...
  13. ncbi Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension
    R B Rothman
    Clinical Psychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA
    Circulation 100:869-75. 1999
    ..Development of new medications that produce neurochemical effects like phen/fen without causing unwanted side effects would be a significant therapeutic breakthrough...
  14. ncbi Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens
    J P Pepper
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, P.O. Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Brain Res Mol Brain Res 87:184-9. 2001
    ..Moreover, these findings suggest that adverse consequences related to altered catecholamine transmission would not occur if patients taking phenelzine, a non-selective MAO inhibitor, relapsed and used cocaine...
  15. ncbi Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addiction
    R B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 914:71-81. 2000
    ..This paper reviews two approaches, based on the dual deficit model, taken by our laboratory to develop medications to treat stimulant abuse...
  16. ncbi Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil
    Dorota Zolkowska
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 329:738-46. 2009
    ..Nondopaminergic mechanisms may also contribute to the pharmacology of modafinil. Finally, the results suggest that modafinil should be tested as an adjunct for treating METH addiction...
  17. ncbi Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters
    Han Yu
    Laboratory of Medicinal Chemistry, Building 8, Room B1-23, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, 20892-0815, USA
    J Med Chem 47:2624-34. 2004
    ..Ex vivo autoradiography, however, demonstrated that iv administration of (-)-(1R,3S)-11 produced a dose-dependent, persistent occupation of 5-HT transporter binding sites but not DA transporter sites...
  18. ncbi In vivo correlates of central serotonin function after high-dose fenfluramine administration
    M H Baumann
    Clinical Psychopharmacology Section, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 844:138-52. 1998
    ..Neuroendocrine challenge tests represent a reliable method to test the existence of FEN-induced neurotoxicity in human patients undergoing long-term FEN treatment...
  19. ncbi Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library
    R B Rothman
    Clinical Psychopharmacology Section, DIR, NIDA, NIH, Baltimore, Maryland, USA
    Synapse 33:239-46. 1999
    ..These data demonstrate that peptides can function as inhibitors of biogenic amine transport. Future work will focus on developing more potent and selective peptides. Published 1999 Wiley-Liss, Inc...
  20. ncbi Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
    R B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, Baltimore, Maryland 21224, USA
    Synapse 39:32-41. 2001
    ..These results suggest that NE may contribute to the amphetamine-type subjective effects of stimulants in humans...
  21. ncbi Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction
    R B Rothman
    Clinical Psychopharmacology Section, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 844:59-74. 1998
    ..The preclinical data obtained with PHEN/FEN in various models of drug provide a strong rationale for pursuing controlled clinical trials in humans with agents that act via a similar mechanism of action...
  22. ncbi Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 333 Cassell Drive, Suite 4500, Baltimore, MD 21224, USA
    Neuroscience 152:773-84. 2008
    ..Our results suggest that MDMA tolerance in humans may reflect 5-HT deficits which could contribute to further dose escalation...
  23. ncbi Neurochemical and neuroendocrine effects of ibogaine in rats: comparison to MK-801
    M H Baumann
    Clinical Psychopharmacology Section, National Institute on Drug Abuse NIDA, National Institutes of Health NIH Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 844:252-64. 1998
    ..Thus, the in vivo mechanism of IBO action cannot be explained simply on the basis of antagonism at NMDA receptors...
  24. ncbi 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein
    Xiaoying Wang
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Synapse 53:240-8. 2004
    ..Viewed collectively with our previous results and other published data, these data indicate that MDMA-induced persistent 5-HT depletion may occur in the absence of axotomy...
  25. ncbi Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease
    Dorota Zolkowska
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 318:604-10. 2006
    ..Additional studies are needed to determine the effects of chronic administration of amphetamines on circulating 5-HT...
  26. ncbi Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phe
    Ling-Wei Hsin
    Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Med Chem 45:1321-9. 2002
    ..In accord with the in vitro data, 6 showed greater potency than 7 in elevating extracellular dopamine levels in a microdialysis assay and in inhibiting cocaine-maintained responding in rhesus monkeys...
  27. ncbi Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan
    X Wang
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, P O Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Neuroscience 148:212-20. 2007
    ..Next, we treated rats with the 5-HT precursor, l-5-hydroxytryptophan (5-HTP), in an attempt to restore MDMA-induced depletions of 5-HT...
  28. ncbi Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 313:1361-9. 2005
    ..0 mg/kg/h. Collectively, the findings reported here demonstrate that nonamphetamine monoamine releasing agents such as PAL-287 might be promising candidate medications for the treatment of stimulant dependence...
  29. ncbi Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis
    Mohab Alexander
    Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Synapse 56:94-9. 2005
    ..Viewed collectively, the present data indicate that typical clinical doses of phentermine and (+/-)-ephedrine may not release central DA in humans, a hypothesis that should ultimately be tested in controlled clinical studies...
  30. ncbi Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction
    Richard B Rothman
    Clinical Psychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 333 Cassell Dr, Baltimore, MD 21224, USA
    Biochem Pharmacol 75:2-16. 2008
    ....
  31. ncbi Serotonergic responsiveness in human cocaine users
    Udi E Ghitza
    Clinical Pharmacology and Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Drug Alcohol Depend 86:207-13. 2007
    ..Studies of human cocaine users given a serotonergic challenge have produced inconsistent results...
  32. ncbi Evidence for alterations in alpha2-adrenergic receptor sensitivity in rats exposed to repeated cocaine administration
    M H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, PO Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Neuroscience 125:683-90. 2004
    ..Since human patients with depression often exhibit blunted GH responses to clonidine, our findings provide evidence that cocaine withdrawal might produce depressive-like symptoms via dysregulation of NE mechanisms...
  33. ncbi Therapeutic potential of monoamine transporter substrates
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Curr Top Med Chem 6:1845-59. 2006
    ..g., fenfluramine) and DA releasers (e.g., amphetamine). Our findings demonstrate the feasibility of developing non-amphetamine releasing agents as potential treatments for substance abuse disorders and other psychiatric conditions...
  34. ncbi Evidence for noncompetitive modulation of substrate-induced serotonin release
    Richard B Rothman
    Clinical Psychopharmacology, IRP, NIDA, NIH, DHHS, Baltimore, Maryland, USA
    Synapse 64:862-9. 2010
    ..Viewed collectively, these findings suggest that it may be possible to design SERT inhibitors that differentially regulate SERT function...
  35. ncbi Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, PO Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Trends Pharmacol Sci 27:612-8. 2006
    ....
  36. ncbi Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs
    Richard B Rothman
    CPS, IRP, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1074:245-60. 2006
    ..Moreover, the relationship between DA and 5-HT releasing potency is an important determinant in developing new agonist medications with reduced stimulant properties...
  37. ncbi Appetite suppressants, cardiac valve disease and combination pharmacotherapy
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institutes of Health, National Institute on Drug Abuse, Department of Health and Human Services, Baltimore, MD 21224, USA
    Am J Ther 16:354-64. 2009
    ....
  38. ncbi Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Dr, Suite 4500, Baltimore, MD 21224, USA
    Drug Metab Dispos 37:2163-70. 2009
    ..Finally, given key similarities between MDMA pharmacokinetics in rats and humans, data from rats may be clinically relevant when appropriate dosing conditions are used...
  39. ncbi Serotonergic drugs and valvular heart disease
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Expert Opin Drug Saf 8:317-29. 2009
    ..One prevailing hypothesis (i.e., the '5-HT hypothesis') suggests that fenfluramine-induced increases in plasma 5-HT underlie the disease...
  40. ncbi Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction
    Richard B Rothman
    Clinical Psychopharmacology Section, IRP NIDA NIH, Clinical Psychopharmacology Section, Suite 4500, Triad building, 333 Cassell Drive, Baltimore, MD 21224, USA
    Exp Clin Psychopharmacol 16:458-74. 2008
    ..It is concluded that DA/5-HT releasers could be useful therapeutic adjuncts for the treatment of cocaine and alcohol addictions, as well as for obesity, attention-deficit disorder, and depression...
  41. ncbi Serotonin (5-HT) transporter ligands affect plasma 5-HT in rats
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, Baltimore, Maryland, USA
    Ann N Y Acad Sci 1139:268-84. 2008
    ..Chronic fenfluramine and fluoxetine have minimal effects on plasma 5-HT, suggesting that the increased risk for IPAH associated with fenfluramine does not depend upon elevations in plasma 5-HT...
  42. ncbi Dopamine/serotonin releasers as medications for stimulant addictions
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, Baltimore, MD, USA
    Prog Brain Res 172:385-406. 2008
    ..It is concluded that DA/5-HT releasers could be useful therapeutic adjuncts for the treatment of cocaine and alcohol addictions as well as for obesity, attention deficit disorder and depression...
  43. ncbi Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, United States
    Pharmacol Biochem Behav 90:208-17. 2008
    ..0001) and with dialysate DA in accumbens and striatum (P<0.001-0.0001). These data support previous work and suggest the complex spectrum of behaviors produced by MDMA involves 5-HT and DA in a region- and modality-specific manner...
  44. ncbi Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA
    AAPS J 9:E1-10. 2007
    ..It is concluded that DA/5-HT releasers might be useful therapeutic adjuncts for the treatment of cocaine and alcohol addiction, obesity, and even attention deficit disorder and depression...
  45. ncbi Effects of stress modulation on morphine-induced conditioned place preferences and plasma corticosterone levels in Fischer, Lewis, and Sprague-Dawley rat strains
    Ivana Grakalic
    Preclinical Pharmacology Section, Behavioral Neuroscience Branch, DHHS NIH NIDA Intramural Research Program, National Institute on Drug Abuse, 5500 Nathan Shock Drive, Baltimore, MD, 21224, USA
    Psychopharmacology (Berl) 189:277-86. 2006
    ..Interestingly, this relationship has not been established in the inbred Fischer (F344) and Lewis (LEW) rat strains that are often used as animal models of susceptibility to drug use...
  46. ncbi Monoamine transporters and psychostimulant drugs
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, PO Box 5180, Baltimore, MD 21224, USA
    Eur J Pharmacol 479:23-40. 2003
    ..Future medications discovery efforts should focus on identifying new compounds which possess the equipotent substrate activity at DAT and SERT, but which lack the adverse effects of stimulants developed decades ago...
  47. ncbi High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain
    Richard B Rothman
    Clinical Psychopharmacology Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Synapse 50:233-9. 2003
    ..These results support the hypothesis that decreases in tissue 5-HT and SERT binding sites induced by D-FEN and PCA reflect neuroadaptive changes, rather than neurotoxic effects...
  48. ncbi Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Peptides 23:2177-80. 2002
    ..The results demonstrated that anti-CRF IgG upregulates mu and beta-adrenergic receptors. We conclude that CRF in the cerebrospinal fluid may exert regulatory effects throughout the brain...
  49. ncbi Substituted amphetamines that produce long-term serotonin depletion in rat brain ("neurotoxicity") do not decrease serotonin transporter protein expression
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 1025:151-61. 2004
    ..These results support the hypothesis that D-FEN- and PCA-induced decreases in tissue 5-HT and SERT binding sites reflect neuroadaptive changes rather than neurotoxic effects...
  50. ncbi Therapeutic and adverse actions of serotonin transporter substrates
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, P O Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Pharmacol Ther 95:73-88. 2002
    ..Such agents may be useful for treating a variety of psychiatric disorders...
  51. ncbi Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, 5500 Nathan Shock Drive, 21224, Baltimore, MD, USA
    Eur J Pharmacol 447:51-7. 2002
    ..The collective findings suggest that phendimetrazine is a "prodrug" that is converted to the active metabolite phenmetrazine, a potent substrate for norepinephrine and dopamine transporters...
  52. ncbi Appetite suppressants as agonist substitution therapies for stimulant dependence
    Richard B Rothman
    Clinical Psychopharmacology Section, NIDA, NIH, Baltimore, Maryland 21224, USA
    Ann N Y Acad Sci 965:109-26. 2002
    ..Future efforts should focus on developing new medications that possess the desired therapeutic activity but lack the adverse effects associated with older amphetamine-type anorectics...
  53. ncbi (+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane
    Xiaoying Wang
    Clinical Psychopharmacology Section, Intramural Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 314:1002-12. 2005
    ....
  54. ncbi Targeted screening for biogenic amine transporters: potential applications for natural products
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, NIDA, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Life Sci 78:512-8. 2005
    ..The potential application of these methods to characterizing natural products will be discussed in reference to results obtained with "purified" natural products, such as ephedrine stereoisomers...
  55. ncbi Serotonin releasing agents. Neurochemical, therapeutic and adverse effects
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, P O Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Pharmacol Biochem Behav 71:825-36. 2002
    ..Viewed collectively, it seems possible to develop new medications that selectively release 5-HT without the adverse effects of PPH, VHD or neurotoxicity. Such agents may have utility in treating a variety of psychiatric disorders...
  56. ncbi (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters
    Richard B Rothman
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Dr, P O Box 5180, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 305:1191-9. 2003
    ..Release of NE and DA evoked by (+)-norfenfluramine is at least partly mediated via NE transporters. Our results emphasize the potential involvement of noradrenergic mechanisms in the actions of fenfluramines...
  57. ncbi The role of corticosterone in food deprivation-induced reinstatement of cocaine seeking in the rat
    Uri Shalev
    Behavioral Neuroscience Branch, IRP NIDA NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 168:170-6. 2003
    ..Here we studied whether food deprivation would reinstate cocaine seeking and whether the stress hormone, corticosterone, is involved in this effect...
  58. ncbi Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications
    R B Rothman
    Clinical Psychopharmacology Section, Division of Intramural Research, National Institute on Drug Abuse, NIH, Baltimore, MD 21224, USA
    Circulation 102:2836-41. 2000
    ..We hypothesized that fenfluramine or its metabolite norfenfluramine and other medications known to produce VHD have preferentially high affinities for a particular serotonin receptor subtype capable of stimulating mitogenesis...
  59. ncbi Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)
    Michael H Baumann
    Clinical Psychopharmacology Section, Intramural Research Program IRP, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Baltimore, Maryland 21224, USA
    Int Rev Neurobiol 88:257-96. 2009
    ..Finally, the MDMA metabolite, 3,4-methylenedioxyamphetamine (MDA), is a potent 5-HT(2B) agonist which could contribute to the increased risk of VHD observed in heavy MDMA users...
  60. ncbi Interaction of amphetamines and related compounds at the vesicular monoamine transporter
    John S Partilla
    Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Dr, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 319:237-46. 2006
    ..Finally, the VMAT(2) assays we have developed should prove useful for guiding the synthesis and evaluation of novel VMAT(2) agents as possible treatment agents for addictive disorders...
  61. ncbi Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels
    Dorota Zolkowska
    Clinical Psychopharmacology, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Heath and Human Services, 5500 Nathan Shock Dr, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 324:791-7. 2008
    ..Furthermore, chronic fenfluramine reduces the ability of acute fenfluramine to increase plasma 5-HT, suggesting that the 5-HT hypothesis cannot explain the increased risk of valvular heart disease in patients treated with fenfluramine...
  62. ncbi Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter
    Richard B Rothman
    Chest 132:1412-3. 2007
  63. ncbi Effects of chronic social stress on neuroendocrine responsiveness to challenge with ethanol, dexamethasone and corticotropin-releasing hormone
    Larissa A Pohorecky
    Center of Alcohol Studies, Rutgers University, 607 Alison Road, Piscataway, NJ 08855 8001, USA
    Neuroendocrinology 80:332-42. 2004
    ..Our data demonstrate that social rank and housing conditions affect plasma PRL and CORT concentrations, and modify responses to EtOH, possibly reflecting impairments of HPA axis regulation in socially-housed rats...
  64. ncbi Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats
    William A Carlezon
    Department of Psychiatry, McLean Hospital, MRC 217, 115 Mill Street, Belmont, MA 02478
    J Pharmacol Exp Ther 316:440-7. 2006
    ....